SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Regeneron Pharmaceuticals expects a $102 million acquired in-process…

REGENERON PHARMACEUTICALS, INC. · 8-K filed Apr 8, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 8, 2026 at 07:05 ET

Regeneron Pharmaceuticals expects a $102 million acquired in-process R&D charge in Q1 2026, which will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81. This is a preliminary estimate ahead of final financial statement closing.

  • Regeneron expects a $102 million acquired in-process research and development (IPR&D) charge in Q1 2026
  • The charge primarily relates to premiums on equity securities purchased, development milestones, and up-front payments from collaboration and licensing agreements
  • The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81
  • The company notes that actual results may differ from these preliminary estimates as financial statements are not yet finalized

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access